NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
NMD Pharma — NMD Pharma
NMD Pharma
Roel Bulthuis - Director at NMD Pharma | The Org
Erhverv Aarhus - 照片| Facebook
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
NMD Pharma - PIR International
NMD Pharma - Inkef capital
NMD Pharma | The Org
Neuromuscular Drug Development Summit (NMD) - Pharma Journalist
Company Presentation
NMD Pharma Information | NMD Pharma Profile
Investors — NMD Pharma
NMD | LinkedIn
Prominent Canadian researcher in Denmark: Why I left a top job in California
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
Big deal: NMD flexes series A muscles - Global University Venturing
Company Presentation
NMD Pharma - Inkef capital
Klaus Wilhardt - Corporate identity, Design, Logo/navnetræk og designguides
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
